Oncology Diagnostics in India: A Market on the Rise
India’s cancer diagnostics market is accelerating. Valued at USD 7.8 billion in 2025, it is projected to reach USD 14.4 billion by 2034, with a CAGR of 7.06% (2026–2034).
Growth drivers:
- Rising cancer incidence & urgent need for timely diagnosis
- Adoption of advanced diagnostic tools
- Ageing population, urbanization, and lifestyle changes
- Government initiatives boosting infrastructure & investments
Key players: Roche, Abbott, Siemens, GE Healthcare, Cipla, Bristol Myers Squibb, Thermo Fisher Scientific.
Market Segmentation (as shown above)
- Consumables (45%) – reagents, kits, antibodies, probes (largest share due to recurring demand)
- Imaging equipment (30%) – X-ray, CT, MRI, PET-CT
- Instruments (15%) – analyzers and platforms
- Tumour marker tests (10%) – biomarker assays
Challenges: High cost of PET-CT and molecular tests, plus limited accessibility in smaller cities.
Future outlook:
AI-driven risk profiling and predictive analytics are set to transform oncology diagnostics, opening new opportunities for innovation and patient care.
💡 AI is poised to redefine cancer diagnostics in India. How do you see this shaping patient outcomes and industry innovation?
#Healthcare #Diagnostics #Oncology #IndiaHealthcare #MedicalInnovation #AIinHealthcare #MarketResearch